486 related articles for article (PubMed ID: 30937470)
21. Optimization of an empiric vancomycin dosing algorithm for improved target concentration attainment in patients with thermal injury.
Hill DM; Velamuri SR; Lanfranco J; Romero Legro I; Sinclair SE; Hickerson WL
Burns; 2019 Mar; 45(2):423-432. PubMed ID: 30340863
[TBL] [Abstract][Full Text] [Related]
22. Vancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance children.
Lv CL; Lu JJ; Chen M; Zhang R; Li QC; Chen YY; Liu TT
J Clin Pharm Ther; 2020 Dec; 45(6):1278-1287. PubMed ID: 32557716
[TBL] [Abstract][Full Text] [Related]
23. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
Frymoyer A; Guglielmo BJ; Hersh AL
Pediatr Infect Dis J; 2013 Oct; 32(10):1077-9. PubMed ID: 23652479
[TBL] [Abstract][Full Text] [Related]
24. Correlation of a Vancomycin Pharmacokinetic Model and Trough Serum Concentrations in Pediatric Patients.
Ploessl C; White C; Manasco K
Pediatr Infect Dis J; 2015 Oct; 34(10):e244-7. PubMed ID: 26121203
[TBL] [Abstract][Full Text] [Related]
25. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation.
Frymoyer A; Hersh AL; Coralic Z; Benet LZ; Joseph Guglielmo B
Clin Ther; 2010 Mar; 32(3):534-42. PubMed ID: 20399990
[TBL] [Abstract][Full Text] [Related]
26. Optimization of Intermittent Vancomycin Dosage Regimens for Thai Critically Ill Population Infected by MRSA in the Era of the "MIC Creep" Phenomenon.
Setiawan E; Suwannoi L; Montakantikul P; Chindavijak B
Acta Med Indones; 2019 Jan; 51(1):10-18. PubMed ID: 31073101
[TBL] [Abstract][Full Text] [Related]
27. Achievement of Therapeutic Vancomycin Trough Serum Concentrations with Empiric Dosing in Neonatal Intensive Care Unit Patients.
Ringenberg T; Robinson C; Meyers R; Degnan L; Shah P; Siu A; Sturgill M
Pediatr Infect Dis J; 2015 Jul; 34(7):742-7. PubMed ID: 25629890
[TBL] [Abstract][Full Text] [Related]
28. Vancomycin AUC
Brandon HH; Burgess DS; Wallace KL; Autry EB; Olney KB
Pharmacotherapy; 2024 Apr; 44(4):294-300. PubMed ID: 38533999
[TBL] [Abstract][Full Text] [Related]
29. Achievement of Therapeutic Vancomycin Exposure With Continuous Infusion in Critically Ill Children.
Genuini M; Oualha M; Bouazza N; Moulin F; Treluyer JM; Lesage F; Renolleau S; Benaboud S
Pediatr Crit Care Med; 2018 Jun; 19(6):e263-e269. PubMed ID: 29394210
[TBL] [Abstract][Full Text] [Related]
30. Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing.
Tang Z; Guan J; Li J; Yu Y; Qian M; Cao J; Shuai W; Jiao Z
Int J Antimicrob Agents; 2021 Mar; 57(3):106300. PubMed ID: 33567334
[TBL] [Abstract][Full Text] [Related]
31. Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients.
Silva DC; Seixas GT; Araujo OR; Arduini RG; Carlesse FA; Petrilli AS
Braz J Infect Dis; 2012; 16(4):361-5. PubMed ID: 22846125
[TBL] [Abstract][Full Text] [Related]
32. Vancomycin dosing and target attainment in children.
Hwang D; Chiu NC; Chang L; Peng CC; Huang DT; Huang FY; Chi H
J Microbiol Immunol Infect; 2017 Aug; 50(4):494-499. PubMed ID: 26462708
[TBL] [Abstract][Full Text] [Related]
33. Initial dosage regimen of vancomycin for septic shock patients: a pharmacokinetic study and Monte Carlo simulation.
Katip Bpharm W; Jaruratanasirikul S; Pattharachayakul S; Wongpoowarak W; Jitsurong A
J Med Assoc Thai; 2014 Nov; 97(11):1209-19. PubMed ID: 25675687
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants.
Chen Y; Wu D; Dong M; Zhu Y; Lu J; Li X; Chen C; Li Z
Eur J Clin Pharmacol; 2018 Jul; 74(7):921-930. PubMed ID: 29602981
[TBL] [Abstract][Full Text] [Related]
35. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
Lodise TP; Drusano GL; Zasowski E; Dihmess A; Lazariu V; Cosler L; McNutt LA
Clin Infect Dis; 2014 Sep; 59(5):666-75. PubMed ID: 24867791
[TBL] [Abstract][Full Text] [Related]
36. A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration.
Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658965
[TBL] [Abstract][Full Text] [Related]
37. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.
DelDot ME; Lipman J; Tett SE
Br J Clin Pharmacol; 2004 Sep; 58(3):259-68. PubMed ID: 15327585
[TBL] [Abstract][Full Text] [Related]
38. Optimizing Vancomycin Use Through 2-Point AUC-Based Therapeutic Drug Monitoring in Pediatric Patients.
Suchartlikitwong P; Anugulruengkitt S; Wacharachaisurapol N; Jantarabenjakul W; Sophonphan J; Theerawit T; Chatsuwan T; Wattanavijitkul T; Puthanakit T
J Clin Pharmacol; 2019 Dec; 59(12):1597-1605. PubMed ID: 31342543
[TBL] [Abstract][Full Text] [Related]
39. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
Padari H; Oselin K; Tasa T; Metsvaht T; Lõivukene K; Lutsar I
BMC Pediatr; 2016 Dec; 16(1):206. PubMed ID: 27931193
[TBL] [Abstract][Full Text] [Related]
40. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
